Sign in
CompletedPhase 4

Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori

Key facts

Who runs it
Nanjing First Hospital, Nanjing Medical University
Where
China13 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
900 people enrolled
Started
20 Jan 2023
Ended
5 Nov 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vonoprazan
  • Amoxicillin
Record updated
19 November 2024

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Ages between 18 and 70 years; Sexes eligible for study: both
  • patients who are diagnosed with Helicobacter pylori with 13C urea breath test or 14C urea breath test
  • treatment-naive patients or patients who failed to eradicate Helicobacter pylori in the past but haven't undergone eradication therapy in the past six months
  • voluntary to be involved in the study and written informed consent was obtained from all patients

Who cannot take part

  • patients who underwent eradication therapy for Helicobacter pylori during the last six months
  • patients who are taking glucocorticoids, non-steroidal anti-inflammatory drugs or anticoagulants
  • patients who have severe concurrent diseases such as hepatic,cardiovascular,respiratory,renal disorders or malignancies
  • allergic reactions to the study drugs
  • patients with peptic ulcer
  • patients who have history of esophageal or gastric surgery
  • MALT lymphoma of stomach or malignant tumor
  • patients who took antibiotics,bismuth agents,probiotics within four weeks prior to treatment and those who took H2 receptor antagonists,proton pump inhibitors(PPIs) or potassium competitive acid blockers within two weeks prior to treatment
  • pregnant or lactating women
  • Alcohol abusers

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study was to evaluate the efficacy and safety of vonoprazan with different doses of amoxicillin for Helicobacter Pylori.

The 3 groups in the trial

  • high dose amoxicillin with vonoprazan groupExisting treatment, for comparison

    vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days

    Treatment: Vonoprazan and Amoxicillin

  • standard dose amoxicillin with vonoprazan groupTreatment being tested

    vonoprazan 20mg bid and amoxicillin 1000mg bid for 14 days

    Treatment: Vonoprazan and Amoxicillin

  • low dose amoxicillin with vonoprazan groupTreatment being tested

    vonoprazan 20mg bid and amoxicillin 500mg tid for 14 days

    Treatment: Vonoprazan and Amoxicillin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori:a Prospective, Multicenter, Open Label, Randomized Controlled Study:
Publications
Record updated
19 November 2024